Strong in-market performance leads STADA Arz to double-digit growth
STADA Arzneimittel (SAZ: Xetra) showed persistence in a challenging operating environment marked by macroeconomic and geopolitical uncertainties to report double-digit sales and earnings growth in the first half of 2022, the German drugmaker reported today.
Organic growth and offering a broader portfolio to patients and healthcare professionals through acquisitions and partnerships enabled STADA to increase adjusted Group sales by 15% to 1.768 billion euros ($1.766 billion) in the first half of 2022. Adjusted for currency fluctuations and special effects, earnings before interest, tax, depreciation and amortization (EBITDA) improved by 23% to 386.5 million euros.
Adjusted sales in STADA’s Consumer Healthcare segment in the first six months of 2022 rose by 25% to 729.2 million euro. Consumer Healthcare accounted for 41% of STADA’s first-half Group sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze